DGNOF (Diagnos) FFO


DGNOF Diagnos Inc DGNOF
16 GF Score
Price $0.18
GF Value $0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Diagnos FFO?

FFO (Funds from operations) only applies to REITs.

DGNOF
16GF Score
Diagnos Inc DGNOF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Diagnos (DGNOF) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnos stock appears to be overvalued. The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05. GuruFocus considers Diagnos to be Significantly Overvalued.

Key valuation signals for DGNOF:

  • FFO:
  • GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score

Get the complete analysis for DGNOF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.05
GF Value